蒽环类/异环磷酰胺为基础的辅助化疗治疗软组织肉瘤的疗效：一项常规和网络 Meta 分析。
Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
机构信息
Cancer center, Union hospital, Tongji medical college, Huazhong university of science and technology, Wuhan, China.
出版信息
J Chemother. 2021 Sep;33(5):319-327. doi: 10.1080/1120009X.2021.1873631. Epub 2021 Jan 27.
The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS. We pooled the hazard ratios of overall survival (OS) and relapse free survival (RFS) by conventional meta-analysis to appraise whether adjuvant chemotherapy benefits STS and performed a network meta-analysis using a Bayesian model to establish the relative ranking of regimens. Nine studies were included in our meta-analysis. The pooled hazard ratios were 0.68 (95%CI: 0.53-0.86) and 0.65 (95%CI: 0.52-0.83) for OS and RFS, respectively. Doxorubicin was indicated as best regimen to benefit OS (probability: 30.2%), while cyclophosphamide + vincristine + doxorubicin + dactinomycin was indicated as the best regimen for RFS (probability: 37.1%). This meta-analysis confirms the positive effect of anthracyclines/ifosfamide-based adjuvant chemotherapy in STS for both OS and RFS.
本研究旨在评估蒽环类/异环磷酰胺为基础的辅助化疗对软组织肉瘤（STS）的疗效，并对 STS 的治疗方案进行相对排序。我们通过常规荟萃分析汇总了总生存（OS）和无复发生存（RFS）的风险比，以评估辅助化疗是否有益于 STS，并使用贝叶斯模型进行网络荟萃分析以确定治疗方案的相对排名。本荟萃分析共纳入 9 项研究。OS 和 RFS 的汇总风险比分别为 0.68（95%CI：0.53-0.86）和 0.65（95%CI：0.52-0.83）。多柔比星被认为是最有益于 OS 的方案（概率：30.2%），而环磷酰胺+长春新碱+多柔比星+放线菌素 D 被认为是最有益于 RFS 的方案（概率：37.1%）。本荟萃分析证实了蒽环类/异环磷酰胺为基础的辅助化疗对 STS 的 OS 和 RFS 的积极影响。
Zotero 插件